ReviewHistology and histopathology2023
Giant cell tumor of bone: An update, including spectrum of pathological features, pathogenesis, molecular profile and the differential diagnoses.
Review in Histology and histopathology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 15 citations in OpenAlex.
- "A Giant Shoulder": Proximal Humerus Giant Cell Tumor Managed With Extended Curettage and Proximal Humerus Internal Locking System Plating with Fibular Strut Graft - A Case Report.Journal of orthopaedic case reports · 2026Article
- Giant cell tumor of bone: exploring HtrA1 as a potential predictor of recurrence.Archives of orthopaedic and trauma surgery · 2026Article
- H3.3G34W immunohistochemistry negative giant cell tumour of bone. Extended analysis of 35 such cases from a single institution in India.Virchows Archiv : an international journal of pathology · 2026Article
- Rare giant cell tumour of the left parieto-occipital skull in an 8-year-old female patient: a case report.BMC surgery · 2026Article
- Metachronous multicentric giant cell tumor of bone with pulmonary metastases: a case report with 20-year follow-up.Frontiers in oncology · 2026Article
- Clinical Audit of Denosumab Biosimilar for Aggressive GCT of Bone: A Tertiary Care Center Retrospective Analysis.South Asian journal of cancer · 2025Article
- Clinical pathological characteristics correlation ofTranslational cancer research · 2025Article
- Molecular pathological insights into tumorigenesis and progression of giant cell tumor of bone.Journal of bone oncology · 2025Review
- Roles of osteoclasts in pathological conditions.Pathology international · 2025Review
- Case Report: Giant cell lesions in the Maxillofacial region: diagnostic points and treatment strategies.Frontiers in oncology · 2025Article
- Establishment and characterization of two novel patient-derived cell lines from giant cell tumor of bone: NCC-GCTB8-C1 and NCC-GCTB9-C1.Human cell · 2024Article
- Recent advances in immunohistochemical and molecular profiling for differential diagnosis between giant cell-rich lesions and tenosynovial giant cell tumors.Frontiers in oncology · 2024Article
- Denosumab combined with microwave ablation excisional scraping for giant cell tumor of the thoracic spine: a case report and literature review.Frontiers in oncology · 2024Article
- Article
- Emerging trends and focus of giant cell tumor of bone research from 2001-2021: A visualization research.Frontiers in oncology · 2022Article
- Clinicopathological correlations and prognostic insights in osteosarcoma: a retrospective analysis.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologieArticle
- Giant Cell Tumor of the Cervical Axis Treated With Anterior-Posterior Surgery and Denosumab: A Ten-year Follow-up Case Report.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Giant cell tumor of bone (GCTB) is an enigmatic tumor. Despite its benign histological appearance and clinical behavior in most cases, it is associated with recurrences, uncommonly metastasis, and rarely with a malignant transformation. During the last few years, there has been a significant evolution in the diagnosis and management of GCTB, including discoveries related to the underlying pathogenesis (RANK/RANK/OPG pathway), with treatment-related implications in the form of denosumab (approved inhibitor for targeting RANKL), leading to improved surgical resections, especially in cases of recurrent, large and borderline resectable tumors. Lately, a specific Histone mutation, namely H3.3G34W underlying almost all GCTBs has been discovered, further leading to the identification of a highly sensitive and specific immunohistochemical antibody marker, H3.3G34W, which is very useful for an exact diagnosis of a GCTB, including its differentiation from its various mimics, which has significant implications. This review describes clinicopathological features of a GCTB, including its variable features, recent concepts, underlying pathogenesis, post-denosumab related changes and various entities that constitute its differential diagnosis, including their molecular signatures, with treatment-related implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.